Table 2.

Intention-to-treat analysis of chronic stress biomarkers for HIGH and MODERATE volume exercise groups in the Breast Cancer and Exercise trial in Alberta (2010−2013) at baseline and 12-months.

Biomarkers	Na	Baseline Mean (95% CI)	12 months Mean (95% CI)	Mean change (95% CI)	Difference in mean change (95% CI)	P-value
Cortisol (nmol/L)
HIGH	195	399.1 (379.0, 419.3)	384.1(363.2, 405.0)	−7.62 (−26, 10.74)	2.69 (−23.5, 28.83)	0.84
MODERATE	191	378.1 (358.4, 397.9)	375.4 (357.9, 392.9)	−10.3 (−28.9, 8.25)
Cortisone (nmol/L)
HIGH	195	65.67 (62.78, 68.57)	65.83 (62.62, 69.04)	0.45 (−2.42, 3.31)	0.61 (−3.46, 4.68)	0.77
MODERATE	191	64.58 (61.51, 67.66)	64.72 (61.53, 67.90)	−0.16 (−3.06, 2.73)
Corticosterone (nmol/L)
HIGH	195	11.53 (10.37, 12.69)	11.48 (9.96, 13.01)	0.48 (−0.73, 1.70)	1.12 (−0.61, 2.85)	0.20
MODERATE	191	9.68 (8.72, 10.63)	9.58 (8.58, 10.58)	−0.64 (−1.86, 0.59)
11-deoxycortisol (nmol/L)
HIGH	194	0.95 (0.86, 1.05)	0.91 (0.82, 1.01)	0.0 (−0.08, 0.08)	0.05 (−0.06, 0.17)	0.37
MODERATE	191	0.82 (0.74, 0.91)	0.81 (0.73, 0.89)	−0.05 (−0.14, 0.03)
Cortisol:cortisone
HIGH	195	6.25 (5.98, 6.51)	6.01 (5.74, 6.27)	−0.19 (−0.40, 0.03)	−0.19 (−0.50, 0.12)	0.23
MODERATE	191	6.00 (5.77, 6.23)	6.06 (5.80, 6.31)	0.0 (−0.22, 0.22)
Cortisol:corticosterone
HIGH	195	46.45 (42.25, 50.65)	48.01 (44.26, 51.75)	0.64 (−2.17, 3.46)	−0.72 (−4.73, 3.29)	0.72
MODERATE	191	50.10 (46.68, 53.52)	50.54 (47.51, 53.57)	1.37 (−1.48, 4.22)
Cortisol:11-deoxycortisol
HIGH	194	525.5 (490.4, 560.7)	535.4 (497.2, 573.5)	1.89 (−30.00, 33.74)	−26.2 (−71.4, 19.14)	0.26
MODERATE	191	564.3 (536.7, 601.9)	584.3 (545.5, 623.0)	28.04 (−4.06, 60.15)

^aOne sample contained invalid measures for 11-deoxycortisol at 12 months due to laboratory error and was excluded from analysis.